Overview
IMDX market data
Price History
IMDX price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$1.65 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.83 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,454.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $2.33 – $8.51 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $131.6M · P/S 67.50.
Company News
Insight Molecular Diagnostics To Host Virtual KOL Event On August 17 To Discuss GraftAssure Platform Leveraging Digital PCR Technology For Reliable dd-cfDNA Results In Transplanted Organ Health MonitoringBenzinga · Aug 11, 2026, 8:17 PM
CORRECTION: Insight Molecular Q2 Adj. EPS $(0.23) Beats $(0.24) Estimate, Sales $239.000K Miss $437.500K EstimateBenzinga · Aug 10, 2026, 10:24 PM
8-K filing — Insight Molecular Diagnostics Inc. (IMDX)SEC EDGAR · Aug 10, 2026, 8:10 PM
Insight Molecular Q2 Adj. EPS $(0.31) Misses $(0.24) Estimate, Sales $239.000K Miss $437.500K EstimateBenzinga · Aug 10, 2026, 8:05 PM
Favorable Medicare Coverage Decision Supports Commercial Adoption of iMDx GraftAssure Assay PortfolioGlobenewswire Inc · Jul 16, 2026, 8:30 PM
Insight Molecular Diagnostics shares are trading higher. The company reported its Q1 financial results.Benzinga · May 14, 2026, 4:24 PM